Search

Author/Creator Shore, Neal

1. 343 Phase 3 study of pembrolizumab + docetaxel and prednisone/prednisolone for metastatic castration-resistant prostate cancer (mCRPC) pretreated with next-generation hormonal agents (NHAs) (KEYNOTE-921). (10th December 2020)

Authors:
Petrylak, Daniel; Shore, Neal; Bennamoun, Mostefa; Ratta, Raffaele; Piulats, Josep; Li, Ben; Schloss, Charles; Fizazi, Karim
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8(2020)Supplement 3
Page Start:
A209
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 343 Phase 3 study of pembrolizumab + docetaxel and prednisone/prednisolone for metastatic castration-resistant prostate cancer (mCRPC) pretreated with next-generation hormonal agents (NHAs) (KEYNOTE-921). (9th November 2020)

Authors:
Petrylak, Daniel; Shore, Neal; Bennamoun, Mostefa; Ratta, Raffaele; Piulats, Josep; Li, Ben; Schloss, Charles; Fizazi, Karim
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8(2020)Supplement 3
Page Start:
A368
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. A Phase I/II study of vesigenurtacel-l (hs-410) or placebo in combination with Bacillus Calmette-Guérin (BCG) in patients with non-muscle invasive bladder cancer (NMIBC). (6th November 2014)

Authors:
Steinberg, Gary D; Shore, Neal; Karsh, Lawrence; Bailen, James; Woods, Michael; Schoenberg, Mark; Schreiber, Taylor H; Price, Melissa
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 2(2014)Supplement 3
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum‐resistant metastatic urothelial cancer. Issue 20 (5th August 2020)

Authors:
Zhang, Tian; Harrison, Michael R.; O'Donnell, Peter H.; Alva, Ajjai S.; Hahn, Noah M.; Appleman, Leonard J.; Cetnar, Jeremy; Burke, John M.; Fleming, Mark T.; Milowsky, Matthew I.; Mortazavi, Amir; Shore, Neal; Sonpavde, Guru P.; Schmidt, Emmett V.; Bitman, Bojena; Munugalavadla, Veerendra; Izumi...
Journal:
Cancer
Issue:
Volume 126:Issue 20(2020)
Page Start:
4485
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Clinical utility of a biopsy-based cell cycle gene expression assay in localized prostate cancer. (April 2014)

Authors:
Shore, Neal; Concepcion, Raoul; Saltzstein, Daniel; Lucia, M. Scott; van Breda, Arletta; Welbourn, William; Lewine, Nicolas; Gustavsen, Gary; Pothier, Kristin; Brawer, Michael K.
Journal:
Current medical research and opinion
Issue:
Volume 30:Number 4(2014:Apr.)
Page Start:
547
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Clinical utility of a biopsy-based cell cycle gene expression assay in localized prostate cancer. (April 2014)

Authors:
Shore, Neal; Concepcion, Raoul; Saltzstein, Daniel; Lucia, M. Scott; van Breda, Arletta; Welbourn, William; Lewine, Nicolas; Gustavsen, Gary; Pothier, Kristin; Brawer, Michael K.
Journal:
Current medical research and opinion
Issue:
Volume 30:Number 4(2014:Apr.)
Page Start:
547
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer. Issue 7 (1st April 2021)

Authors:
Ledet, Elisa M.; Burgess, Earle F.; Sokolova, Alexandra O.; Jaeger, Ellen B.; Hatton, Whitley; Moses, Marcus; Miller, Patrick; Cotogno, Patrick; Layton, Jodi; Barata, Pedro; Lewis, Brian E.; Nakazawa, Mari; Zhu, Jason; Dellinger, Beth; Elrefai, Sara; Nafissi, Nellie N.; Egan, Jan B.; Shore, Neal;...
Journal:
Prostate
Issue:
Volume 81:Issue 7(2021)
Page Start:
433
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region. (December 2021)

Authors:
De Giorgi, Ugo; Hussain, Maha; Shore, Neal; Fizazi, Karim; Tombal, Bertrand; Penson, David; Saad, Fred; Efstathiou, Eleni; Madziarska, Katarzyna; Steinberg, Joyce; Sugg, Jennifer; Lin, Xun; Shen, Qi; Sternberg, Cora N.
Journal:
European journal of cancer
Issue:
Volume 159(2021)
Page Start:
237
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial. (September 2021)

Authors:
Smith, Matthew R.; Shore, Neal; Tammela, Teuvo L.; Ulys, Albertas; Vjaters, Egils; Polyakov, Sergey; Jievaltas, Mindaugas; Luz, Murilo; Alekseev, Boris; Kuss, Iris; Le Berre, Marie-Aude; Mohamed, Ateesha F.; Odom, Dawn; Bartsch, Jennifer; Snapir, Amir; Sarapohja, Toni; Fizazi, Karim
Journal:
European journal of cancer
Issue:
Volume 154(2021)
Page Start:
138
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗